Sitagliptin (Januvia®) 25 and 50 mg tablets
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000877
English
Authors' recommendations:
Sitagliptin (Januvia®) 25 and 50 mg tablets are recommended as an option for use within NHS Wales for the improvement of glycaemic control in type 2 diabetes mellitus patients with moderate renal impairment (CrCl = 30 to < 50 ml/min), severe renal impairment (CrCl < 30 ml/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/sitagliptin%20%28Januvia%29%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Pyrazines
- Triazoles
- Dipeptidyl-Peptidase IV Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.